Josh Woolley, MD, PhD, explains why current active placebos fail to mask high-dose psilocybin trials and outlines a framework proposed to fix it.
News|Articles|August 1, 2024
Psychiatry Month in Review: July 2024
Author(s)Chelsie Derman
This month in review captures the top news in the psychiatry field during July.
Advertisement
Advertisement
This Month in Review for July encompasses the top US Food and Drug Administration (FDA) news, pipeline updates, and discovered associations in the psychiatry field. The recap also captures insights from psychiatry experts on topics ranging from schizophrenia to PTSD. On the latter subject, the Month in Review includes commentary from a psychiatry expert on the potential game-changer MDMA-assisted therapy, with an FDA decision now less than a month away in August.
Related to this article
SOCS leaders explain SOCS Serves, a toolkit-based program connecting dermatology volunteers with students and underserved communities.
EMBARQ-CSU1 and EMBARQ-CSU2 showed sustained reductions in urticaria, with the antibody meeting all primary and key secondary endpoints at Week 12.
The FDA-approved update adds phase 3 HYPERION data on adults diagnosed with PAH within the past year.
Raj Chovatiya, MD, PhD, on zasocitinib results in the scalp, nails, palms and soles, speed of response and once-daily oral dosing in psoriasis.
Philadelphia-area PAH specialists discuss real-world patient mismatch with trial criteria, drug sequencing, and insurance access barriers.
FDA expands marstacimab approval to children and patients with inhibitors, backed by new BASIS trial data.
Frances Lee, MD, on stigma's role in ALD care and why women may progress to advanced disease faster than men.
Advertisement
Advertisement